

aforementioned nucleic acids.

Please substitute the paragraph in the appendix entitled "Clean Version of the Paragraph Beginning at Line 6, Page 23" for the paragraph beginning at line 6, page 23 of the specification. Specific amendments to this paragraph are detailed in the following marked-up paragraph:

Probes:

Salm63: 5'-TCGACTGACTTCAGCTCC-3' (SEQ ID NO:1)

NonSalm: 5'-GCTAACTACTTCTGGAGC-3' (SEQ ID NO:2)

Fluorescence dye used: Cy3

Please substitute the paragraph in the appendix entitled "Clean Version of the Paragraph Beginning at Line 36, Page 27" for the paragraph beginning at line 36, page 27 of the specification. Specific amendments to this paragraph are detailed in the following marked-up paragraph:

Batch of two milk samples of 25 mL each or 25 g for hybridization with the probes

"Salm63-Cys" (Cy3-5'-TCGACTGACTTCAGCTCC-3' (SEQ ID NO:1)) and

"nonSalm-Cy3" (Cy3-5'-GCTAACTACTTCTGGAGC-3' (SEQ ID NO:2))

Please substitute the paragraph in the appendix entitled "Clean Version of the Paragraph Beginning at Line 28, Page 36" for the paragraph beginning at line 28, page 36 of the specification. Specific amendments to this paragraph are detailed in the following marked-up paragraph:

Materials:

- Eppendorf 1.5 mL reaction vessels
- Formamide (Merck, Darmstadt)
- Probe working solutions of 50 ng/ $\mu$ L each:

25  $\mu$ L PPx3 655-Cy3: 5'-ACC CTC CTC TCC CGG TCT-3' (SEQ ID NO:3)

As an alternative to PPx3 655-Cy3, it is also possible to use PPx3 1428-Cy3

PPx3 1428-Cy3 5'-TGG CCC ACC GGC TTC GGG-3' (SEQ ID NO:4)

25  $\mu$ L Non15-Cy3 5'-GCT AAC TAC TTC TGG AGC-3' (SEQ ID NO:5)

25  $\mu$ L Non15-Cy5 5'-GCT AAC TAC TTC TGG AGC-3' (SEQ ID NO:5)

25  $\mu$ L 3xEUB-Cy3I. 5'-GCT GCC TCC CGT AGG AGT-3' (SEQ ID NO:6)

II. 5'-GCA GCC ACC CGT AGG TGT-3' (SEQ ID NO:7)

- III. 5'-GCT GCC ACC CGT AGG TGT-3' (SEQ ID NO:8)
- 25 µL 3xEUB-Cy5I. 5'-GCT GCC TCC CGT AGG AGT-3' (SEQ ID NO:6)
- II. 5'-GCA GCC ACC CGT AGG TGT-3' (SEQ ID NO:7)
- III. 5'-GCT GCC ACC CGT AGG TGT-3' (SEQ ID NO:8)

### In the Claims

Please substitute the claim set in the appendix entitled Clean Version of Pending Claims for the previously pending claim set. The substitute claim set is intended to reflect amendment of claim 27. The specific amendments to claim 27 are detailed in the following marked up claim.

27. (AMENDED) A kit according to Claim 26, containing the nucleic acid probes

Salm63: 5'-TCGACTGACTTCAGCTCC-3' (SEQ ID NO:1)

and

NonSalm: 5'-GCTAACTACTTCTGGAGC-3' (SEQ ID NO:2)

or a nucleic acid probe that differs from Salm 63 and/or NonSalm by a deletion and/or an addition, whereby the ability of this probe to hybridize with Salmonella-specific nucleic acid is maintained, or a nucleic acid that can hybridize with the aforementioned nucleic acids.

### Remarks

Claim 27 has been amended; the pending claims are claims 1-27.

This Supplemental Preliminary Amendment and the above-referenced SEQUENCE LISTING are filed to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted on even date herewith to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington VA 22202. The contents of the paper version of the SEQUENCE LISTING and the computer readable form being submitted to Box Sequence on even date herewith are the same and do not include new matter.